Skip to main content
≥99.0% HPLC Verified • SEPA Bank & Crypto • Min. Order €220
GH Secretagogues 3 min read

Tesamorelin: N-Terminally Modified GHRH Analogue, Visceral Adiposity, and IGF-1 Kinetics

Compiled & reviewed by SwissLab Analytical Chemistry & QC Team — Chromatography, Mass Spectrometry & Solubility Review Desk
Editorial Standards
Analytical Summary

A pharmacological review of Tesamorelin ([trans-3-hexenoyl]-GHRH 1-44). The 3-hexenoyl lipophilic modification, DPP-4 enzymatic resistance, and pituitary receptor binding. Tesamorelin is a synthetic 44-amino acid polypeptide analogue of human Growth Hormone Releasing Hormone (GHRH 1-44).

Key Research Takeaways
  • Tesamorelin is a synthetic 44-amino acid polypeptide analogue of human Growth Hormone Releasing Hormone (GHRH 1-44).
  • Incorporates a trans-3-hexenoyl lipophilic fatty acid group attached to the N-terminal Tyr1 residue.
  • The trans-3-hexenoyl modification confers superior resistance to dipeptidyl peptidase-4 (DPP-4) cleavage compared to native GHRH.
  • Stimulates physiological, pulsatile growth hormone secretion, elevating hepatic IGF-1 synthesis without disrupting negative feedback loops.
  • Exhibits potent lipolytic effects specifically targeting visceral adipose tissue (VAT) in metabolic models.
Analytical & Handling Reference Matrix
CAS Registry Number 218949-48-5
Molecular Formula C221H366N72O67S
Molecular Mass 5135.86 g/mol
Primary Biological Target Pituitary GHRH Receptor (GHRH-R)
Analytical Purity Standard ≥99.0% (RP-HPLC, C18, 214/220 nm)
Identity Verification ESI-MS (±0.1 Da) + Karl Fischer Moisture (<3.0%)
Lyophilized Storage -20°C desiccated, protected from UV light (24–36 months)
Reconstituted Storage 2°C–8°C refrigerated (up to 28 days in 0.9% BA BAC water)

1. Chemical Structure and the Trans-3-Hexenoyl Group

Native human GHRH is a 44-amino acid peptide that is rapidly inactivated in vivo by dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal Tyr1-Ala2 dipeptide within minutes. Tesamorelin solves this pharmacokinetic limitation by acylating the N-terminal Tyr1 amino group with a trans-3-hexenoyl moiety (a 6-carbon unsaturated lipophilic tail). This steric modification blocks DPP-4 binding while preserving high-affinity binding to the GHRH receptor.

2. Pituitary GHRH Receptor Agonism and Pulsatile Dynamics

Upon binding GHRH receptors on somatotrophs in the anterior pituitary, Tesamorelin activates the Gs alpha subunit / adenylate cyclase / cAMP signaling cascade. This triggers the synthesis and pulsatile release of endogenous growth hormone (GH). Crucially, because Tesamorelin operates through native receptor mechanisms, somatostatin negative feedback remains intact, avoiding excessive, non-physiological GH spikes.

3. Visceral Adipose Tissue (VAT) Lipolysis Mechanisms

In clinical and experimental metabolic research, Tesamorelin specifically stimulates triglyceride lipolysis in deep visceral adipocytes, which express high densities of growth hormone receptors. GH stimulates hormone-sensitive lipase (HSL) and downregulates lipoprotein lipase (LPL), mobilizing visceral free fatty acids and reducing ectopic hepatic fat accumulation.

4. Laboratory Reconstitution and Solution Stability

Tesamorelin is a large 5.1 kDa polypeptide supplied as a sterile lyophilized powder with mannitol buffer. Reconstitute with 2.0 mL sterile Bacteriostatic Water by gentle swirling. Store refrigerated at 2°C to 8°C and protect from direct light exposure.

5. Bench Preparation & Assay Reproducibility for Tesamorelin

When designing in-vitro experiments targeting Pituitary GHRH Receptor (GHRH-R), normalize dosing across replicates by molar concentration (µM or nM) using the published molecular weight (5135.86 g/mol) and batch counterion composition rather than gross powder weight alone. Log lot numbers, diluent pH, and aliquot dates to ensure batch-to-batch reproducibility across longitudinal experiments.

Peer-Reviewed References & Analytical Standards

  1. Ferdinandi E.S. et al. (2007). Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic & Clinical Pharmacology & Toxicology, 100(1), 49–58. [PMID: 17214611 ↗]
  2. Falutz J. et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. [PMID: 18057338 ↗]

Referenced Laboratory Research Reagents

Batch-verified SwissLab catalog entries cited in this monograph

All 66 Compounds →
Laboratory Compliance & Handling Protocol

All analytical monographs and chemical data are published strictly for in-vitro laboratory research and scientific reference. Reagents must be handled by qualified personnel wearing appropriate PPE. Not for human or veterinary use.

Related Research Monographs

All monographs (44)

Your Research Cart

0 items selected • Min. order €220

SEPA Bank Transfer & Crypto (BTC, ETH, USDT, USDC, SOL, XMR)
Min €220

Your cart is empty

Browse our catalog of research peptides and reagents (minimum order €220).

Browse Catalog